Recent mouse models and vaccine candidates for preventing chronic/latent tuberculosis infection and its reactivation

Abstract Tuberculosis (TB) remains a major challenge in public health worldwide. Until today, the only widely used and approved vaccine is the Mycobacterium bovis bacille Calmette–Guerin (BCG). This vaccine provides a highly variable level of protection against the active, pulmonary form of tubercul...

Full description

Saved in:
Bibliographic Details
Published in:Pathogens and disease 2017-08, Vol.75 (6)
Main Authors: Pedroza-Roldán, César, Flores-Valdez, Mario Alberto
Format: Article
Language:English
Subjects:
Activation
Animal models
Animals
Antigens
Bacillus Calmette-Guerin vaccine
Bacteria
BCG
Chronic infection
Disease Models, Animal
Disease Transmission, Infectious - prevention & control
Drug Discovery - methods
Drug Discovery - trends
Humans
Infections
Latency
Latent Tuberculosis - prevention & control
Mice
Mycobacterium tuberculosis - immunology
Proteomics
Public health
Rodents
Sputum
Tuberculosis
Tuberculosis Vaccines - administration & dosage
Tuberculosis Vaccines - immunology
Vaccines
Vaccines, Attenuated - administration & dosage
Vaccines, Attenuated - immunology
Vaccines, Subunit - administration & dosage
Vaccines, Subunit - immunology
Citations: Items that this one cites
Items that cite this one
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Tuberculosis (TB) remains a major challenge in public health worldwide. Until today, the only widely used and approved vaccine is the Mycobacterium bovis bacille Calmette–Guerin (BCG). This vaccine provides a highly variable level of protection against the active, pulmonary form of tuberculosis, and practically none against the latent form of TB infection. This disparity in protection has been extensively studied, and for this reason, several groups have focused their research on the quest for attenuated vaccines based on M. tuberculosis or on the identification of latency-associated antigens that can be incorporated into modified BCG, or that can be used as adjuvanted subunit vaccines. In order to seek new potential antigens relevant for infection, some researchers have performed experiments with highly sensitive techniques such as transcriptomic and proteomic analyses using sputum samples from humans or by using mouse models resembling several aspects of TB. In this review, we focus on reports of new mouse models or mycobacterial antigens recently tested for developing vaccine candidates against chronic/latent tuberculosis and its reactivation. A review of newer mouse models and vaccine candidates for chronic and latent and reactivated TB.
ISSN:2049-632X
2049-632X
DOI:10.1093/femspd/ftx079